Singular Genomics Systems Stock Return On Equity
| OMIC Stock | USD 0.38 0.01 1.62% |
Singular Genomics Systems fundamentals help investors to digest information that contributes to Singular Genomics' financial success or failures. It also enables traders to predict the movement of Singular Stock. The fundamental analysis module provides a way to measure Singular Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Singular Genomics stock.
| Last Reported | Projected for Next Year | ||
| Return On Equity | (0.53) | (0.50) |
Singular | Return On Equity |
Singular Genomics Systems Company Return On Equity Analysis
Singular Genomics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Singular Genomics Return On Equity | -0.43 |
Most of Singular Genomics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Singular Genomics Systems is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Singular Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Singular Genomics is extremely important. It helps to project a fair market value of Singular Stock properly, considering its historical fundamentals such as Return On Equity. Since Singular Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Singular Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Singular Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Singular Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Singular Genomics Systems has a Return On Equity of -0.4317. This is 98.2% lower than that of the Health Care Equipment & Supplies sector and 92.78% lower than that of the Health Care industry. The return on equity for all United States stocks is 39.26% higher than that of the company.
Singular Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Singular Genomics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Singular Genomics could also be used in its relative valuation, which is a method of valuing Singular Genomics by comparing valuation metrics of similar companies.Singular Genomics is currently under evaluation in return on equity category among related companies.
Singular Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (23.39) % | ||||
| Current Valuation | (68.35 M) | ||||
| Shares Outstanding | 74.07 M | ||||
| Shares Owned By Insiders | 14.01 % | ||||
| Shares Owned By Institutions | 47.17 % | ||||
| Number Of Shares Shorted | 667.17 K | ||||
| Price To Earning | 35.71 X | ||||
| Price To Book | 0.18 X | ||||
| Price To Sales | 10.86 X | ||||
| Revenue | 2.91 M | ||||
| Gross Profit | (24 K) | ||||
| EBITDA | (86.5 M) | ||||
| Net Income | (94.82 M) | ||||
| Cash And Equivalents | 287.98 M | ||||
| Cash Per Share | 4.05 X | ||||
| Total Debt | 75.29 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 22.98 X | ||||
| Book Value Per Share | 2.42 X | ||||
| Cash Flow From Operations | (73.65 M) | ||||
| Short Ratio | 5.95 X | ||||
| Earnings Per Share | (1.30) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 0.75 | ||||
| Number Of Employees | 255 | ||||
| Beta | 1.43 | ||||
| Market Capitalization | 28.46 M | ||||
| Total Asset | 265.47 M | ||||
| Retained Earnings | (337.6 M) | ||||
| Working Capital | 173.94 M | ||||
| Net Asset | 265.47 M |
About Singular Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Singular Genomics Systems's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Singular Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Singular Genomics Systems based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| C | Citigroup | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out Singular Genomics Piotroski F Score and Singular Genomics Altman Z Score analysis. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Singular Stock analysis
When running Singular Genomics' price analysis, check to measure Singular Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Singular Genomics is operating at the current time. Most of Singular Genomics' value examination focuses on studying past and present price action to predict the probability of Singular Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Singular Genomics' price. Additionally, you may evaluate how the addition of Singular Genomics to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Singular Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.30) | Revenue Per Share 0.04 | Quarterly Revenue Growth 0.413 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.